Peroxisome proliferator-activated receptor

protein

PPAR-mediated cardioprotective peroxisome-proliferator signaling is attenuated in post-MI myocardial stunning and heart-failure progression.

Pathway placement

Cascade stepOff-pathway / systemic markers

Confidencelow

RationaleCardioprotective signaling pathway; reduced in myocardial stunning.

Druggability

Not assessed (no mapped human gene target).

Type I vs Type II discrimination

ScoresShared / rises in both

R — rupture / Type-I

C — confounder / Type-II

A — assay feasibility

E — evidence strength

T1DI (composite)

Specificity differential (R−C)+5.6

Confounder panel (Type-II drivers)

1sepsis / systemic inflammationmag 2

2anemia / acute blood lossn/a

3hypovolemia / dehydrationmag 1

4tachyarrhythmiamag 2

5hypoxemia / respiratory failuremag 2

6hypertensive emergencymag 2

7high-demand / peri-operative stressmag 2

Coverage: 6/7 confounders with evidence

Tier: deep-scored (abstract-extracted) · 20 supporting references. See the discrimination table for all markers.

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.

Specimen

Serum or plasma

Collection tube

Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)

Method / principle

Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists

Reagent / substrate

Matched anti-target antibody pair (capture + labeled detection)

Platform

ELISA microplate or multiplex (Luminex/MSD)

Turnaround · availability

Send-out / research · Research-grade (no universal clinical assay)